ADAP
Adaptimmune Therapeutics

9,779
Loading...
Loading...
News
all
press releases
An Overview of Adaptimmune Therapeutics's Earnings
read more...
Benzinga·10mo ago
News Placeholder
More News
News Placeholder
Adaptimmune Enhances Severance Benefits for Executives
Adaptimmune Therapeutics (ADAP) has issued an update. Adaptimmune Therapeutics plc updated their executive severance policy, enhancing the benefits...
TipRanks Financial Blog·1y ago
News Placeholder
Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are up 18% this past week, but still in the red over the last three years
It is a pleasure to report that the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) is up 99% in the last quarter. But...
Simply Wall St·1y ago
News Placeholder
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...
Newsfile Corp. - News Releases·1y ago
News Placeholder
Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 2.1%
Adaptimmune Therapeutics plc (NASDAQ:ADAP Get Free Report) fell 2.1% on Tuesday . The company traded as low as $1.41 and last traded at $1.41. 62,343 shares were traded during trading, a...
Ticker Report·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adaptimmune Therapeutics (ADAP Research Report), Elevation Oncology...
TipRanks Financial Blog·2y ago
News Placeholder
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
Key Financial Highlights and Business UpdatesRelated Stocks: ADAP...
GuruFocus·2y ago
News Placeholder
Buy Rating Affirmed for Adaptimmune on Upcoming Milestones and Promising Trial Results
Adaptimmune Therapeutics (ADAP Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy...
TipRanks Financial Blog·2y ago
News Placeholder
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed...
Newsfile Corp. - News Releases·2y ago
News Placeholder
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Decrease in Short Interest
Adaptimmune Therapeutics plc (NASDAQ:ADAP Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest...
Zolmax·2y ago

Latest ADAP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.